Vaping in today's pandemic: E-cigarette, or vaping, product use-associated lung injury mimicking COVID-19 in teenagers presenting with respiratory distress.
Daphne O DarmawanKriti GwalBrian D GoudySanjay JhawarKiran NandalikePublished in: SAGE open medical case reports (2020)
The clinical presentation of children and adolescents infected with severe acute respiratory syndrome coronavirus 2 can range from asymptomatic to mild or moderate manifestations. We present a case series of three adolescents who presented during the coronavirus disease 2019 (COVID-19) pandemic with symptoms concerning for COVID-19, including fever, abdominal symptoms, cough, respiratory distress, and hypoxemia. Their laboratory results showed elevated inflammatory markers that are also commonly seen in COVID-19. The chest imaging studies mimicked COVID-19 with non-specific ground glass opacities and interstitial prominence patterns. However, severe acute respiratory syndrome coronavirus 2 testing was negative and further questioning of these adolescents and their parents revealed a history of vaping marijuana-related products leading to the eventual diagnosis of e-cigarette, or vaping, product use-associated lung injury. Our patients were successfully treated with corticosteroids. The providers caring for pediatric patients, especially adolescents, should continue to have a high index of suspicion for e-cigarette, or vaping, product use-associated lung injury in patients presenting with unexplained respiratory failure, while ruling out COVID-19.
Keyphrases
- coronavirus disease
- respiratory syndrome coronavirus
- sars cov
- young adults
- physical activity
- respiratory failure
- end stage renal disease
- smoking cessation
- high resolution
- extracorporeal membrane oxygenation
- newly diagnosed
- intensive care unit
- mechanical ventilation
- peritoneal dialysis
- photodynamic therapy
- acute respiratory distress syndrome
- respiratory tract